Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Executive Summary

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line
Advertisement

Related Content

Medco Suits Complicate Merck Spin-Off Plans, Position In Medicare Debate
Medco In Settlement Talks With U.S. Attorney; Chance To Write PBM Rules?
Medco Lets Snow Reign: CEO David Snow Joins PBM From WellChoice
IG Compliance Guide Will Change PBM Rebate Policies, AdvancePCS Says
Senate Medicare Rx Work Begins; Merck Joins In Frist Briefing
Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year
Medco Will Disclose Drug Cost After Rebates, Discounts Under Settlement
West Virginia Suit Vs. Medco Will Test Claim That PBM Favors Merck Drugs
Rx Rebates, Gifts To Physicians Would Be Public Under Torricelli Proposal
Merck Minus Medco Sets Ambitious Margin Benchmark: 82% On Pure Rx
Advertisement
UsernamePublicRestriction

Register

PS040156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel